- Hangzhou unicorn joins hands with top-tier hospital to roll out the assistant “Guan Xiao Ling”
- System integrates hospital data, remote monitoring and automated clinical alerts, targeting continuous, full-cycle care for coronary heart disease patients
Hangzhou-based digital healthcare unicorn Weimai (微脉) has partnered with West China Hospital to launch what it labels China’s first AI agent for end-to-end coronary heart disease management, aiming to close long-standing gaps between hospital treatment and long-term patient monitoring.
The system, named “Guan Xiao Ling,” was unveiled in Chengdu, capital of southwestern Sichuan Province, on April 12. It was co-developed over more than a year by Weimai’s Zhejiang provincial AI institute for full-disease-cycle management and a clinical team led by cardiologist He Yong at West China Hospital of Sichuan University.
Coronary heart disease remains one of China’s most prevalent cardiovascular conditions, requiring continuous monitoring across diagnosis, treatment and rehabilitation.
However, fragmented follow-up systems and limited post-discharge tracking have long been cited as weaknesses in standard care pathways.
West China Hospital is widely regarded as one of China’s leading medical institutions, particularly in complex clinical care and tertiary hospital services.
The AI agent aggregates medical records, laboratory results and discharge summaries to build individualized patient profiles and generate personalized long-term management plans.
It is designed to continuously monitor risk indicators and issue alerts to patients, family members and clinical teams when abnormal patterns are detected, with the goal of enabling earlier intervention and reducing acute episodes.
The system also coordinates follow-up workflows such as medication reminders, rehabilitation guidance, appointment scheduling and lifestyle interventions, effectively acting as a structured care “navigation layer” for patients outside the hospital.
In addition, “Guan Xiao Ling” can ingest real-time data from external monitoring devices, including heart rate, blood pressure and glucose levels, alongside follow-up notes and consultation records, and adjust care plans dynamically based on changing conditions, according to Weimai.
“Under a structured management plan, the system functions like a autonomous navigation system, continuously guiding patients and families through actionable steps,” said Zhou Yuyang, executive dean of Weimai’s AI institute for full-disease-cycle management, speaking at the launch event.
Weimai, founded in 2015, operates an AI-driven chronic and full-cycle care platform, positioning itself in a model similar to Managed Care Organizations in the United States and working closely with public hospitals across China to extend care beyond clinical visits.
According to Chinese media reports, its network had reached about 4,700 hospitals and medical institutions by early 2025, including deep partnerships with 157 public hospitals.
